Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

L Goyal, SK Saha, LY Liu, G Siravegna, I Leshchiner… - Cancer discovery, 2017 - AACR
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising
therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The …
被引用次数：469 相关文章

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

L Goyal, SK Saha, LY Liu, G Siravegna… - Cancer …, 2016 - europepmc.org
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising
therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The …
[HTML] nih.gov

[HTML][HTML] Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma

L Goyal, SK Saha, LY Liu, G Siravegna… - Cancer …, 2017 - ncbi.nlm.nih.gov
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising
therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The …

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

L Goyal, SK Saha, LY Liu, G Siravegna, I Leshchiner… - Cancer …, 2017 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Genetic alterations in the fibroblast growth
factor receptor (FGFR) pathway are promising therapeutic targets in many cancers, including …

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma

L Goyal, SK Saha, LY Liu, G Siravegna… - Cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising
therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The …

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma

L Goyal, SK Saha, LY Liu, G Siravegna… - CANCER …, 2017 - iris.unito.it
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising
therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The …

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

L Goyal, SK Saha, LY Liu, G Siravegna… - Cancer …, 2016 - europepmc.org
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising
therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The …